Subscribe to RSS
DOI: 10.1055/s-2003-40681
Lebensbedrohliches malignes neuroleptisches Syndrom unter Olanzapin
Life Threatening Neuroleptic Malignant Syndrome Due to OlanzapinePublication History
Publication Date:
21 July 2003 (online)
![](https://www.thieme-connect.de/media/psychiat-praxis/200305/lookinside/thumbnails/10.1055-s-2003-40681-1.jpg)
Zusammenfassung
Das Vorkommen eines malignen neuroleptischen Syndroms (MNS) unter atypischen Neuroleptika ist selten. Wir berichten von einer 49-jährigen Patientin, welche 12 Tage nach einer Reexposition mit Olanzapin ein schweres lebensbedrohliches MNS ausbildete. Neben intensivmedizinischer Therapie erfolgten neun Elektrokrampfbehandlungen (EKT), die bilaterale EKT führte zu klinischer Stabilisierung. Zum Entlassungszeitpunkt (> 2 Monate nach Episodenbeginn) bestand weitgehende Remission. Anamnestisch war 14 Monate zuvor bereits ein schweres MNS unter einer Aufdosierung mit Clozapin und 4 Wochen nach Haldol-Decanoat-Injektion eingetreten.
Abstract
The frequency of neuroleptic malignant syndrome (NMS) after clozapine or olanzapine is low and often of non-serious nature. A 49 year-old female patient developed NMS 12 days after olanzapine re-exposure. Olanzapine was stopped, the patient was transferred to an ICU and received a course of nine uni- and bilateral ECT treatments. This led to remission. 14 months earlier the patient had presented with a first severe NMS episode after haloperidol depot injection and 4 days after starting oral clozapine. Following the first NMS episode olanzapine (20 mg per day) was administered for 11 months without adverse effects.
Literatur
- 1 Aboraya A, Schumacher J, Abdalla E, Le Page J, McGhee M, Butcher D, Griffin H, Shahda M. Neuroleptic malignant syndrome associated with risperidone and olanzapine in first-episode schizophrenia. The West Virginia Medical Journal. 2002; 98 63-65
- 2 Apple J E, Hauer G. Neuroleptic malignant syndrome associated with olanzapine. Psychosomatics. 1999; 40, 3 267-268
- 3 Burkhard P R, Vingerhoets F JG. Olanzapine-induced neuroleptic malignant syndrome. Arch Gen Psychiatry. 1999; 56 101-102
- 4 Filice G A, Mc Dougall B C, Ercan-Fang N, Billington C J. Neuroleptic malignant syndrome associated with olanzapine. The Annals of Pharmacotherapy. 1998; 32 1158-1159
- 5 Gheorghiu S, Knobler H Y, Drumer D. Recurrence of neuroleptic malignant syndrome with olanzapine treatment. Am J Psychiatry. 1999; 156 1836
- 6 Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry. 1998; 155 1113-1116
- 7 Järventausta K, Leinonen E. Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment. Acta Psychiatr Scand. 2000; 102 231-233
- 8 Johnson V, Bruxner G. Neuroleptic malignant syndrome associated with olanzapine. Australian and New Zealand Journal of Psychiatry. 1998; 32 884-886
- 9 Karagianis J L, Phillips L C, Hogan K P, LeDrew K K. Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature. Ann Pharmacother. 1999; 33 623-630
- 10 Marcus E L, Vass A, Zislin J. Marked elevation of serum creatine kinase associated with olanzapine therapy. The Annals of Pharmacotherapy. 1999; 33 697-699
- 11 Margolese H, Chouinard G. Olanzapine-induced neuroleptic malignant syndrome with mental retardation. Am J Psychiatry. 1999; 156 1115-1116
- 12 Moltz D A, Coeytaux R R. Case Report. Possible neuroleptic malignant syndrome associated with olanzapine. J Clin Psychopharmacol. 1998; 18 485-486
- 13 Nyfort-Hansen K, Alderman C P. Possible neuroleptic malignant syndrome associated with olanzapine. The Annals of Pharmacotherapy. 2000; 34 667
- 14 Pelonero A L, Levenson J L, Pandurangi A K. Neuroleptic malignant syndrome: a review. Psychiatric Services. 1998; 49 1163-1172
- 15 Philibert R A, Adam L A, Frank F M. et al . Olanzapine usage associated with neuroleptic malignant syndrome. Psychosomatics. 2001; 42 528-529
- 16 Reeves R R, Torres R A, Liberto V, Hart R H. Atypical neuroleptic malignant syndrome associated with olanzapine. Pharmacotherapy. 2002; 22 641-644
- 17 Sierra-Biddle D, Herran A, Diez-Aja S, Gonzales-Mata J M, Vidal E, Diez-Manrique F, Vázquez-Barquero J L. Neuroleptic malignant syndrome and olanzapine. J Clin Psychopharm. 2000; 20 704-705
- 18 Stanfield S C, Privette T. Neuroleptic malignant syndrome associated with olanzapine therapy: a case report. The Journal of Emergency Medicine. 2000; 19 355-357
- 19 Tsai G, Crisostomo G, Rosenblatt M, Stern T A. Neuroleptic malignant syndrome associated with clozapine treatment. Annals of Clinical Psychiatry. 1995; 7 91-96
- 20 Weller M, Kornhuber J. Clozapin: Risikoneuroleptikum für die Auslösung eines malignen neuroleptischen Syndroms (MNS) oder neuroleptische Alternative bei positiver MNS-Anamnese. Fortschr Neurol Psychiat. 1993; 61 217-222
- 21 Assion H J, Heinemann F, Laux G. Neuroleptic malignant syndrome under treatment with antidepressants? A critical review. Eur Arch Psychiatry Clin Neurosci. 1998; 248 231-239
- 22 Bhana N, Perry C M. Olanzapine. A review of its use in the treatment of bipolar I disorder. CNS Drugs. 2001; 15 871-904
- 23 Garcia G, Ghani S, Poveda R A, Dansky B L. Neuroleptic malignant syndrome with antidepressant/antipsychotic drug combination. The Annals of Pharmacotherapy. 2001; 35 784-785
- 24 Harradine P G, Williams S E, Doherty S R. Neuroleptic malignant syndrome: an underdiagnosed condition. MJA. 2001; 174 593-594
- 25 Heinemann F, Assion H J, Laux G. Malignes neuroleptisches Syndrom unter der Behandlung mit Antidepressiva. Fortschr Neurol Psychiat. 1997; 65 208-213
- 26 Levinson D F, Simpson G M. Neuroleptic-induced extrapyramidal symptoms with fever. Arch Gen Psychiatry. 1986; 43 839-842
- 27 Shalev A, Munitz H. The Neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand. 1986; 73 337-347
- 28 Pope H G, Keck P E, Mcelroy S L. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry. 1986; 143 1227-1233
- 29 Reddig S, Minnema A M, Tandon R. Neuroleptic malignant syndrome and clozapine. Annals of Clinical Psychiatry. 1993; 5 25-27
ERRATUM
Leider wurden in diesem Artikel die falschen Abbildungen abgedruckt. Nachstehend finden Sie die korrekte Version. Wir bitten Sie, unser Versehen zu entschuldigen.
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
Abb. 1 Zahlenspanne vorwärts/Wechsler Memory Scale - revised.
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
Abb. 2 Zahlenspanne rückwärts/Wechsler Memory Scale - revised.
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
Abb. 3 Mittelfristige Behaltensleistung/Münchner Verbaler Gedächtnistest.
Dr. med. Andrea Kopf
Klinik und Poliklinik für Psychiatrie · Universitätsklinikum Leipzig · AöR
Liebigstraße 22
04103 Leipzig